Argenica Therapeutics Limited (ASX:AGN)

Market Cap	23.76M -76.8%
Revenue (ttm)	1.01M -67.3%
Net Income	-9.80M
EPS	-0.08
Shares Out	128.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,443
Average Volume	151,703
Open	0.1950
Previous Close	0.1950
Day's Range	0.1850 - 0.1950
52-Week Range	0.1300 - 0.8500
Beta	0.77
RSI	51.83
Earnings Date	May 11, 2026

About Argenica Therapeutics

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AGN

Financial Performance

In fiscal year 2025, Argenica Therapeutics's revenue was 3.21 million, an increase of 23.70% compared to the previous year's 2.60 million. Losses were -7.17 million, 30.9% more than in 2024.